Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.
This report contains a comprehensive listing of asset purchase deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of asset purchase deals.
Chapter 4 provides a review of the leading asset purchase deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
The deal directory includes a comprehensive listing of all asset purchase deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2019.
In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse asset purchase deals
- Benchmark analysis - identify market value of transactions
- Financials - headline, upfront, milestone, royalty rates
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
The report focuses on four primary types of asset available for purchase:
- Business assets
- Product assets
- Royalty assets
- Technology assets
This report contains a comprehensive listing of asset purchase deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of asset purchase deals.
Chapter 4 provides a review of the leading asset purchase deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
The deal directory includes a comprehensive listing of all asset purchase deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2019.
In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.
Report Scope
Asset Purchase Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.Asset Purchase Deals in Pharmaceuticals and Biotechnology includes:
- Trends in asset purchase dealmaking in the life sciences industry
- Overview of asset purchase deal structure
- Directory of asset purchase deal records covering pharmaceuticals, biotechnology, medical devices and diagnostics
- The leading asset purchase deals by value
- Most active asset purchase dealmakers
- The leading asset purchase partnering resources
In Asset Purchase Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the rights granted or optioned?
- What rights are granted by the agreement?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are intellectual property rights handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Chapter 1 - Introduction
Chapter 2 - Trends in asset purchase dealmaking
Chapter 3 - Overview of asset purchase deal structure
Chapter 4 - Leading asset purchase deals
Chapter 5 - Top 25 most active asset purchase dealmakers
Chapter 6 - Asset purchase deals including contracts directory
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3B Pharmaceuticals
- 3CL Sciences
- 4D Molecular Therapeutics
- 9 Meters Biopharma
- 30 Technology
- Aadi Bioscience
- Aardvark Therapeutics
- Abbvie
- Abcam
- AbCellera Biologics
- Acacia Research
- Achaogen
- AC Immune
- Acino Pharma
- Aclaris Therapeutics
- Acorda Therapeutics
- Acrotech Biopharma
- Actelion
- Adalvo
- Adamis Pharmaceuticals
- Adapsyn Bioscience
- Adello Biologics
- Adhera Therapeutics
- Adial Pharmaceuticals
- adMare BioInnovations
- Adovate
- Advanced Neural Dynamics
- Advanced Tear Diagnostics
- ADvantage Therapeutics
- Advanz Pharma
- Advent International
- Aelix Therapeutics
- Aethon Therapeutics
- Aevitas Therapeutics
- AFFiRiS
- AGC Biologics
- Agios Pharmaceuticals
- Akorn
- Alaya.bio
- Alcon Laboratories
- Aleph Farms
- Alexion Pharmaceuticals
- Alfasigma
- Algernon Pharmaceuticals
- ALK-Abello
- Allergan
- Allergan Aesthetics
- Alliance Pharma
- Ally Biotech
- Almirall
- Altaris Capital Partners
- Altavant Sciences
- Alvogen
- Alvotech
- Amerigen Pharmaceuticals
- AmerisourceBergen
- Amgen
- AMMTeK
- Amneal Pharmaceuticals
- Ampersand Capital Partners
- Amphastar Pharmaceuticals
- AmplifyBio
- Amplyx Pharmaceuticals
- Amylyx Pharmaceuticals
- Amyris
- Angelini Pharma
- ANI Pharmaceuticals
- Antares Pharma
- Apeiron Biologics
- ApoPharma
- Apotex
- Aradigm
- Araris Biotech
- aratinga.bio SAS Group
- Arcadia Consumer Healthcare
- Ardena
- argenx
- ArisGlobal
- Arkuda Therapeutics
- Arranta Bio
- Arrevus
- ARS Pharmaceuticals
- Artisan Bio
- Arvinas
- Asarina Pharma
- Ascend Advanced Therapies
- Asklepios Biopharmaceutical
- Aspargo Laboratories
- Aspen Holding
- Aspen Pharmacare Canada
- Assembly Biosciences
- Assertio Therapeutics
- AstraZeneca
- Astrea Pharma
- Atara Biotherapeutics
- Athenex
- Atnahs Pharma
- ATP
- Atreca
- AUG Therapeutics
- AuraGen Aesthetics
- Aurora Cannabis
- AuxoCell Laboratories
- Avalo Therapeutics
- Avicanna
- Avrobio
- AXIM Biotechnologies
- Ayala Pharmaceuticals
- Aytu BioPharma
- Basilea Pharmaceutica
- Bausch & Lomb
- Bausch Health Companies
- Bavarian Nordic
- Baxter International
- Bayer
- Bayer Animal Health
- B Braun
- Beacon Therapeutics
- Beartooth Therapeutics
- Beckley Psytech
- Beiersdorf
- Bellicum Pharmaceuticals
- Bellus Health
- Benuvia Therapeutics
- BetterLife Pharma
- Biocon
- BioDelivery Sciences
- Biodelta Nutraceuticals
- Biogen
- BioGene Technology
- Bio Innovation Group
- BioMotiv
- BioNTech
- BioNxt Solutions
- BiopharmX
- BioReference Laboratories
- BioStem Technologies
- BioSyent
- BioVaxys
- Bioventus
- BioVie
- Bluebird Bio
- Blue Water Biotech
- Blue Water Vaccines
- Blumentech
- BMG Pharmaceuticals
- Boehringer Ingelheim
- Bolt Biotherapeutics
- Bone Therapeutics
- Bora Pharmaceuticals
- Boston Scientific
- Botanix Pharmaceuticals
- Brickell Biotech
- BridgeBio Pharma
- Bridge Medicines
- Bridgewest Group
- Brii Biosciences
- Bristol-Myers Squibb
- Bruker
- CanAm Bioresearch
- Candel Therapeutics
- Cannabis Manufacturer’s Guild
- Cannara Biotech
- Castle Biosciences
- Catalent
- Catalyst Biosciences
- CBC Group
- Cedars-Sinai Medical Center
- Celator
- Celgene
- Cell Biosciences
- Celling Biosciences
- Cellistic
- CellReady
- Celltrion
- Celyad
- CeraVx
- Cerecor
- Cheplapharm Arzneimittel
- Chiesi Farmaceutici
- Chimagen Biosciences
- China Pharma Holdings
- Cilag AG
- Cinven
- Cipher Pharmaceuticals
- Cipla
- Circadian Wellness
- Clarus Therapeutics
- Clovis Oncology
- Co.Don
- Codexis
- Codiak BioSciences
- Coeptis Pharmaceuticals
- Coherus Biosciences
- Collegium Pharmaceuticals
- Concert Pharmaceuticals
- Context Therapeutics
- ConvaTec
- Cook Medical
- Cooper Companies
- Corden Pharma
- CORXEL Pharmaceuticals
- Corza Medical
- Cosette Pharmaceuticals
- Covestro
- Covis Pharmaceutical
- Covistat
- Crosswalk Therapeutics
- CTI BioPharma
- Cullinan Oncology
- Curaleaf
- Curon Biopharmaceutical
- Cybin
- Cyclerion Therapeutics
- Cynata Therapeutics
- Cyprium Therapeutics
- Cytokinetics
- CytoMed Therapeutics
- Daiichi Sankyo
- DAS Therapeutics
- Delpharm
- Denovo Biopharma
- Dermira
- DermOQ
- Desert Medical Campus
- Desma HC
- DeuteRx
- DiagnaMed
- DifGen Pharmaceuticals
- Dong-A Pharmaceutical
- Dr. Reddy's Laboratories
- Dren Bio
- DSM
- DSM Nutritional Products
- Dualogics
- Durect
- Dutch Emotional Brain
- Eckert & Ziegler
- Eddingpharm
- Eden Biologics
- EdiGene
- Edison Nation
- Editas Medicine
- Edwards Lifesciences
- Eiger BioPharmaceuticals
- Elanco
- Elekta
- Eli Lilly
- Eluminex Biosciences
- Emerald Health Therapeutics
- Emergent BioSolutions
- Empyrean Medical Systems
- Encore Medical
- EndoCeutics
- Endonovo Therapeutics
- Endo Ventures
- Entheon Biomedical
- EnWave
- Enzyvant Science
- EPI Health
- Equillium
- Erytech Pharma
- Essential Pharma
- Essential Pharmaceuticals
- Eterna Therapeutics
- Ethicon Endo-Surgery
- Eton Pharmaceuticals
- Eurobio Scientific
- Evonik Industries
- Exacis Biotherapeutics
- Exelixis
- Expedeon
- Eyevance
- Finch Therapeutics
- Firsthand Technology
- Flagship Biosciences
- Flamma
- FORMA Therapeutics
- Fox Chase Chemical Diversity Center
- Fresh Tracks Therapeutics
- Freya Pharma Solutions
- Fujifilm
- Fujifilm Diosynth Biotechnologies
- Fusion Pharmaceuticals
- G&W Laboratories
- Galapagos
- Galderma
- Galecto
- GamaMabs Pharma
- GC Pharma
- Genentech
- Genezen
- Gilead Sciences
- Ginkgo BioWorks
- Givaudan
- GL Capital Group
- Glenmark Pharmaceuticals
- Glycotope Biotechnology
- Gowan Crop Protection
- Gravitas Therapeutics
- Greenteaspoon
- GRI Bio
- Grifols
- Grunenthal
- GSK
- GT Biopharma
- GT Medical Technologies
- H-CYTE
- Halo Labs
- Harrow Health
- Havn Life Sciences
- Healion Bio
- Healiva
- HeavenlyRx
- Hera Biotech
- Heritage Group
- Heritage Pharmaceuticals
- High Ridge Brands
- Hikma Pharmaceuticals
- Hillstream BioPharma
- HLS Therapeutics
- HMNRTH
- Howard Foundation
- HS Pharmaceuticals
- HTL Biotechnology
- Hubro Therapeutics
- Humanetics
- Hutchison China MediTech
- Hypera Pharma
- I-mab
- iAnthus Capital
- IASO Biotherapeutics
- iCAD
- Icagen
- IconOVir Bio
- Idorsia
- IFM Therapeutics
- Iktos
- IlmixGroup
- ImaginAb
- ImmunGene
- ImmunityBio
- ImmunoCellular Therapeutics
- Immunome
- Imugene
- IMV
- Inceptor Bio
- Incyte
- InflammX Therapeutics
- Innate Pharma
- Innovent Biologics
- Inozyme Pharma
- Inserm
- Intas Pharmaceuticals
- Integrative Medicine
- Intermountain Precision Genomics
- International Process Plants
- Interpace BioPharma
- Invitae
- Ionic Brands
- Ipsen
- IsoPlexis
- IsoRay
- Iveric Bio
- Ixaka
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Pharmaceutica NV
- Jolt Health
- Journey Medical
- JT Pharmaceuticals
- Juvise Pharmaceuticals
- Kaken Pharmaceutical
- Kala Pharmaceuticals
- Kancera
- Kane Biotech
- Kapoose Creek Bio
- Karo Pharma
- Kashiv BioSciences
- KBP BioSciences
- KD Pharma
- Kedrion
- KemPharm
- Kincell Bio
- Kinnate Biopharma
- Kite Pharma
- Klogenix
- Korsch
- Kronos Bio
- Kuros Biosciences
- Laboratoires DELBERT
- Laboratoire Serb
- Laboratoires Thea
- Laboratorio Medinfar
- Laboratorios Rubio
- Laboratory Corporation of America
- Landos Biopharma
- Lannett
- LEO Pharma
- Les Laboratoires Servier
- Lexicon Pharmaceuticals
- LGC
- LI-COR Biosciences
- Lifecycle Biotechnologies
- Lifenet
- Ligand Pharmaceuticals
- Lighthouse Pharmaceuticals
- Liminal BioSciences
- LineaRx
- Link Fund Solutions
- Link Immunotherapeutics
- Lobe Sciences
- Lobesity Pharma
- Longitude Capital
- Lonza
- Lorem Vascular
- LOTTE
- LTL Pharma
- Lucy Scientific Discovery
- Luminera
- LumiraDx
- Lumos Pharma
- MAB Discovery
- MabVax Therapeutics
- Macrogen
- Macrogenics
- MacuHealth
- Mainz Biomed
- Mandos
- MannKind Biopharmaceuticals
- Maravai LifeSciences
- Marinus Pharmaceuticals
- Marker Therapeutics
- MAWD Pathology
- Mayne Pharma
- MD Anderson Cancer Center
- Medican Enterprises
- Medicure
- Medline Industries
- Mednax
- Meilleur Technologies
- Meitheal Pharmaceuticals
- Melinta Therapeutics
- Menarini Asia-Pacific
- Merck and Co
- Merck Animal Health
- Merck KGaA
- Meridian Bioscience
- Merrimack Pharmaceuticals
- Merz Therapeutics
- Microba Life Sciences
- MiGenTra
- Mikart
- MilliporeSigma
- Minapharm
- Mind Medicine
- Mirum Pharmaceuticals
- MITEM PHARMA
- Mithra Pharmaceuticals
- Mitralign
- Moberg Pharma
- Modern Meadow
- Modulus Therapeutics
- Molecular Assemblies
- MorphoSys
- Mountain Valley MD
- Mubadala Investment Company
- Mucokinetica
- Mustang Bio
- Mylan Laboratories
- MyLife Technologies
- Myovant Sciences
- Myriad Genetics
- Naari Pharma
- Nabriva Therapeutics
- Nanjing King-friend Biochemical Pharmaceutical
- NanoProteagen
- Natera
- National Resilience
- Navidea Biopharmaceuticals
- NEC OncoImmunity
- Negev Labs
- Nektar Therapeutics
- Neogen
- Nephron Pharmaceuticals
- Neptune Wellness Solutions
- Nestle
- Nestle Health Science
- NeuBase Therapeutics
- Neuraxpharm
- NeurMedix
- NeuroBo Pharmaceuticals
- Neuropathix
- Nevakar
- Newport Research
- New York Blood Center
- Nexelis
- Nextmune
- Nika Pharmaceuticals
- NImmune Biopharma
- NLC Pharma
- NOHO
- Noramco
- Nora Pharma
- North American Partners in Anesthesia
- NovaBay Pharmaceuticals
- NovAccess Global
- Novan
- Novartis
- Novavax
- Noventia Pharma
- NovImmune
- Novo Nordisk
- Nufarm
- NYU Langone Medical Center
- Oakrum Pharma
- ObsEva
- Ocugen
- Odyssey Health
- Oncopeptides
- OncoQuest
- Ono Pharmaceutical
- OpenBiome
- OPKO Health
- Opus Genetics
- Oragenics
- Organovo
- Orgenesis
- Orifarm
- Orphazyme
- Orsenix
- Orum Therapeutics
- OSE Immunotherapeutics
- OS Therapies
- Otonomy
- Otsuka America Pharmaceutical
- PACT Pharma
- Padagis
- Palatin Technologies
- Palisade Bio
- PanTheryx
- ParaPRO
- Pascal Biosciences
- Patagonia Pharmaceuticals
- PaxMedica
- PEAR Therapeutics
- PentixaPharm
- Performance Health
- Periphagen Holdings
- Perrigo
- Perspective Therapeutics
- PetIQ
- Pfizer
- Pharmaceutical Associates
- Pharmanovia
- Pharmapar
- Pharmaron
- PharmaTher
- PhaseBio Pharmaceuticals
- Phenomics Health
- Phoenixus
- Physician Recommended Nutriceuticals
- Pierre Fabre
- Piramal
- Pixium Vision
- Plus Therapeutics
- PLx Pharma
- Poolbeg Pharma
- Precera Bioscience
- Precisa Medical Instruments
- Pressure BioSciences
- Prestige Consumer Healthcare
- PreveCeutical Medical
- Primavera Capital Group
- ProBioGen
- ProKidney
- Proliant Health and Biologicals
- Promius Pharma
- ProQR Therapeutics
- Proteus Digital Health
- Prothelia
- Prothena
- Psomagen
- Pulmokine
- Puration
- PureTech Health
- Purnovate
- QIAGEN
- QPS
- Quince Therapeutics
- Radius Health
- Rafarma Pharmaceuticals
- Rakuten Medical
- Rasna Therapeutics
- Real Brands
- Realm Therapeutics
- Recipharm
- Reckitt Benckiser
- Recordati
- Rediscovery Life Sciences
- Regor Therapeutics
- ReLive Biotechnologies
- Relmada Therapeutics
- Resilience
- Retinagenix
- Revive Therapeutics
- Rexgenero
- Roche
- Rohner
- Roivant Sciences
- Rosemont Pharmaceuticals
- RoundTable Healthcare Partners
- RoverMed BioSciences
- Rumpus Therapeutics
- Saladax Biomedical
- Salarius Pharmaceuticals
- Samsung Bioepis
- Samsung Biologics
- Sandoz
- Sanofi
- Santen Pharmaceutical
- Saol Therapeutics
- Sarcomatrix Therapeutics
- Savant HWP
- Scailyte
- Scantox
- Science Corporation
- Scion Solutions
- Sebacia
- Selenity Pharmaceuticals
- Seneca
- Sensus Healthcare
- Sentynl Therapeutics
- Septerna
- Serenity Bioworks
- Seres Therapeutics
- Seyltx
- Sharps Technology
- Shenzhen Beimei Pharmaceuticals
- Shoppers Drug Mart
- Shoreline Biosciences
- Shorla Oncology
- Sibannac
- Sienna Biopharmaceuticals
- Sientra
- Sigma Analytical Services
- Signet Healthcare Partneers
- Silk Road Therapeutics
- Simtra BioPharma Solutions
- SIT Laboratorio Farmaceutico
- Skin Products
- Sloan Pharma
- Smith & Nephew
- SOCPRA Sciences Sante et Humaines
- SofPulse
- Sofregen Medical
- Sohm
- Sol-Gel
- Sonic Healthcare
- Sorse Technology
- Sosei
- Southern Research Institute
- Spectrum Pharmaceuticals
- Spiral Therapeutics
- Sproutly
- STADA Arzneimittel
- Stark Investments
- SugarLeaf Labs
- Sumitomo Dainippon Pharma
- Sumitovant Biopharma
- Sun Pharmaceutical
- Sunstar Suisse
- Supernus Pharmaceuticals
- Swedish Orphan Biovitrum
- Synergy Pharmaceuticals
- Syngene
- Synsight
- Syros Pharmaceuticals
- Taiho
- Takeda Pharmaceutical
- Talaris Therapeutics
- Tamir Biotechnology
- Targovax
- TekCyte
- Teligent
- Telix Pharmaceuticals
- Terran Biosciences
- TerSera Therapeutics
- Teva Pharmaceutical Industries
- Teva Pharmaceuticals USA
- The Green Organic Dutchman Holdings
- Therakind
- Therapeutic Solutions International
- ThermiGen
- Thermo Fisher Scientific
- Tilray
- Titan Pharmaceuticals
- Tiziana Life Sciences
- Tocagen
- Todos Medical
- Tolmar
- TONIX Pharmaceuticals
- Transcend Biodynamics
- Transgene
- Travere Therapeutics
- Trigemina
- TriLink BioTechnologies
- TuHURA Biopharma
- TuHURA Biosciences
- Tulex Pharmaceuticals
- uBiome
- uBriGene Biosciences
- UCB
- Unicycive Therapeutics
- UniQure
- Universal Display
- University of Helsinki
- Upsher-Smith
- Urgo Laboratories
- UroGen Pharma
- Urovant Sciences
- US Compounding
- US WorldMeds
- Valo Health
- Valo Therapeutics
- Varian Biopharmaceuticals
- Vaximm
- Vaxxel
- VBI Vaccines
- VBL Therapeutics
- Vera Therapeutics
- Vertex Pharmaceuticals
- Veru
- Viamet Pharmaceuticals
- Viatris
- Vibliome Therapeutics
- ViewPoint Therapeutics
- Vifor Pharma
- Virbac
- Visus Therapeutics
- Vitatex
- Vtesse
- Vyera Pharmaceuticals
- VYNE Therapeutics
- Walgreens
- Warburg Pincus
- Warp Drive Bio
- Wellspring Ophthalmics
- Wesana Health
- Windtree Therapeutics
- Wockhardt
- WraSer Pharmaceuticals
- Wuhan Humanwell
- WuXi Biologics
- Wuxi STA
- Xbiome
- XBiotech
- Xbrane Biopharma
- Xcelerate Solutions
- Xellia Pharmaceuticals
- Xoma
- Xspire Pharma
- Yield10 Bioscience
- Yumanity Therapeutics
- Zealand Pharma
- Zentiva
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
